SecBot SecBot

LMAT

LEMAITRE VASCULAR INC
Nasdaq· Surgical & Medical Instruments & Apparatus· CIK 0001158895 Healthcare & Medical Devices
$77.01 −1.28 (−1.63%)
Nov 16 4:00 PM ET · prev $78.29
Market cap
$1.8B
Small cap
Consensus
Buy
64% Buy or better · 14 analysts
Median target
$91.00
+18% · range $81.00–132.00
1 year
−11.5%
from $86.99 · Nov 17
30 days
−6.4%
from $82.31
52-week range
$77.01–117.39
at the low
Avg volume 20D
289.2K
shares / day
Short interest
1.66M
≈7.2% of shares · −6.7%
Days to cover
6.2
at average volume
Insider net
$0
no open-market trades · since Jun 4
New fund stakes
1
Q3 2026 13F · 1 exit
Filing reports
13
analyzed by SecBot
SecBot read BEARISH 4 reports · 90 days
Balance 1 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/4

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells since Jun 4. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q3 2026: 26 added (1 new), 22 trimmed or exited. Largest new: Boston Trust Walden $28.5M.

  • AnalystsBULLISH

    9 of 14 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest −6.7% to 1.66M shares. 6.2 days to cover, ≈7.2% of shares.

  • TrendDOWNTREND

    5% below its 50-day average. New closing low $77.01 on Nov 16.

Who's buying

13F· Q3 2026
1
new positions
1
exit
$28.5M
in new stakes
FundMoveSharesValue
JPMORGAN CHASE & CODOUBLED408,821$34.0M
UBS Group AGADD352,144$29.1M
Boston Trust Walden CorpNEW345,634$28.5M
VOYA INVESTMENT MANAGEMENT LLCDOUBLED238,914$19.7M
PRINCIPAL FINANCIAL GROUP INCADD151,779$12.5M
Rockefeller Capital Management L.P.ADD144,408$11.9M
PUBLIC SECTOR PENSION INVESTMENT BOARDADD111,357$9.2M
ProShare Advisors LLCADD102,571$8.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

14 analysts
Buy 64% rate it Buy or better
Strong Buy5Buy4Hold5Sell0Strong Sell0
12-month targets · 7 analysts

Price is below the lowest target. Median implies +18%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 5, 2026Wells Fargo
MAINTAIN
MAINTAINEqual-Weight
Nov 5, 2026Citizens
MAINTAIN
MAINTAINMarket Outperform
Aug 5, 2026Wells Fargo
MAINTAIN
MAINTAINEqual-Weight
Jun 3, 2026Barrington Research
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
open-market buys or sells · since Jun 4
DateInsiderTypeValue
Sep 3, 2026
Roberts David B
President and Director
Sep 3, 2026
AWARD5.287 sh
Sep 3, 2026
Roberts David B
President and Director
Sep 3, 2026
AWARD0.345 sh
Sep 3, 2026
Roberts David B
President and Director
Sep 3, 2026
AWARD0.306 sh
Sep 3, 2026
Roberts David B
President and Director
Sep 3, 2026
AWARD3.576 sh
Sep 3, 2026
Roberts David B
President and Director
Sep 3, 2026
AWARD3.157 sh
Sep 3, 2026
Roberts David B
President and Director
Sep 3, 2026
AWARD4.352 sh
Sep 3, 2026
Roberts David B
President and Director
Sep 3, 2026
AWARD3.632 sh
Sep 3, 2026
Roberts David B
President and Director
Sep 3, 2026
AWARD2.126 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY$3.15$2.97–$3.30-0.9%$303.4M

Short side

FINRA· Oct 30, 2026
1,656,867
shares short
-6.7%
vs prior settlement
6.2
days to cover
≈7.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 6, 2026 Other
LeMaitre to Participate in Upcoming Investor Conferences
BURLINGTON, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced
Nov 4, 2026 SEC
LeMaitre Vascular reported Q3 2026 sales of $68.0M (+11% YoY) and GAAP diluted EPS of $0.65, missing the $0.69…
8-K · Impact 6/10
Nov 2, 2026 SEC
Three asset managers added or initiated LMAT positions in Q3 2026, with Boston Trust Walden opening a $28.5M new stake…
INST-CLUSTER · Impact 3/10
Oct 15, 2026 SEC
President David B. Roberts notified LeMaitre Vascular of his retirement as an employee and President, effective…
8-K · Impact 2/10
Sep 30, 2026 Inst.
JPMORGAN CHASE & CO · DOUBLED
408,821 shares ($34.0M)
Sep 30, 2026 Inst.
UBS Group AG · ADD
352,144 shares ($29.1M)
Sep 3, 2026 Insider
Roberts David B was granted 5.287 shares
President and Director
Sep 3, 2026 Insider
Roberts David B was granted 0.345 shares
President and Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Nov 6, 2026
Press release
LeMaitre to Participate in Upcoming Investor Conferences
BURLINGTON, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three…
Nov 4, 2026
Earnings result
LMAT Q3 2026 Earnings: EPS $0.65 (-7.1% vs est)
Aug 27, 2026
Announcement
LeMaitre to Participate at Upcoming Investor Conferences in September
BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three…
Aug 6, 2026
Press release
LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference
BURLINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will hold investor…
Aug 4, 2026
Earnings
LeMaitre Q2 2026 Financial Results
BURLINGTON, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services…

SecBot reports

13 filings · 1 press release · 2 bullish · 3 bearish · 8 neutral
All LMAT filing & press-release reports (14)